ProQR Therapeutics N.V.
- PRQR
- NASDAQ
- Biotechnology
- RNA Therapeutics
- Genetic Disorder Drugs
$1.31
Quote Oct 19, 2026, 08:00 PM UTC
−28.42%over the last month
Max drawdown −31.1%From 1-month high −31.1%3 months −30.3%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About ProQR Therapeutics
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10).
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
166
Market value
$138.0M
Quote Oct 19
Analyst target
$3.00
+129.0% from here
Floor
$1.17
10.4% below price
Resistance
$1.44
9.7% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about PRQRPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free